Skip to main content
. 2016 Feb 26;8(2):240–246. doi: 10.4330/wjc.v8.i2.240

Table 1.

Summary of included trials

Ref. Trial acronym Yr BD-DES type PP-DES type Total patients BD-DES patients PP-DES patients
Natsuaki et al[8] NEXT 2013 Biolimus Everolimus 3235 1617 1618
Smits et al[9] COMPARE 2 2013 Biolimus Everolimus 2707 1795 912
Gao et al[10] TARGET 1 2013 Sirolmus Everolimus 458 227 231
Byrne et al[11] ISAR-TEST 4 2011 Sirolimus Everolimus 2603 652 1304
Xu et al[12] 2011 Sirolimus Zotarolimus 324 168 156
Separham et al[13] 2011 Biolimus Everolimus 200 100 100
Meredith et al[14] EVOLVE 2012 Biolimus Everolimus 192 98 94
Pilgrim et al[15] BIOSCIENCE 2014 Sirolimus Everolimus 2119 1063 1056
Serruys et al[7] ABSORB 2 2014 Everolimus Everolimus 501 335 166
Lee et al[16] 2014 Biolimus Everolimus 500 245 255
Windecker et al[17] BIOFLOW 2 2014 Sirolimus Everolimus 452 298 154

BMS: Bare metal stents; PP-DES: Permanent polymer drug eluting stents; BD-DES: Biodegradable polymer drug eluting stents.